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UVB induces MVP release in a PAF dependent manner in skin-derived epithelial cell line
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Results

Abstract
Ultraviolet-B (UVB) irradiation of the skin can result in both acute
inflammation and systemic immunosuppression. These effects are mediated
by the release of bioactive molecules (e.g. cytokines and lipids) from resident
skin epithelial and immune cells. Our lab has previously determined that UVB
exposure stimulates the production of an inflammatory phospholipid
activator, platelet-activating factor (PAF) and its oxidized analogs, which are
involved in mediating the UVB responses. Due to the fact that UVB radiation
is absorbed by the epidermis but causes systemic effects, we are interested in
examining the PAF-mediated mechanisms of systemic intercellular
communication. Microvesicle particles (MVP) are small membrane-derived
vesicles released from the plasma membrane that can facilitate intercellular
transport of bioactive molecules. We have previously reported that UVB
induces MVPs in a PAF-dependent manner, but the mechanism is not fully
characterized. It has been reported that in other cell types non-UVB cell
stressors require sphingomyelin catabolic activity of acid sphingomyelinase
(aSMase) and kinase-mediated signaling cascades for MVP release. In this
study, both UVB and CPAF (PAFR agonist), stimulated MVP release in various
skin-derived epithelial cell lines. The PAF dependence of UVB-mediated MVP
release was confirmed utilizing a PAF antagonist and PAFR +/- cell lines.
Imipramine, a small-molecule inhibitor of aSMase effectively blocked CPAFand UVB-mediated MVP release suggesting that aSMase activity is required
for these responses. Interestingly, CPAF mediated MVP release was
suppressed by NF-ƙB, ERK ½, JNK, p38 MAPK and ROCK1 small molecule
inhibitors, while UVB-mediated MVP release was only suppressed by the JNK,
p38 MAPK, and ROCK1 inhibitors. These findings suggest common and
distinct pathways between the two stimuli. Subsequently, this study has
confirmed the role of PAF, lipid remodeling, and robust kinase signaling in
UVB and PAF-mediated MVP release. The targeting of such mechanisms of
UVB-mediated MVP release could have potential therapeutic benefits in
mitigating
UVB-induced
acute
inflammation
and
systemic
immunosuppression.
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Figure 2. UVB and CPAF induced MVP release in HaCaT and NTERT cells.
Cells were either treated with no treatment, CPAF (53.9 ng) or 3,600 J/m2
UVB and then incubated for 4 hours. For both treated groups (CPAF and UVB)
there was a significant increase in MVP release compared to the no
treatment group. The data depicted are mean ± SE MVP per ml per 100,000
cells. Groups were compared using one-way ANOVA. Differences in samples
were considered significant with P value less than 0.05. P<0.05 (*), P<0.01
(**).

Figure 5. Effect of PAFR antagonist (WEB 2086) on CPAF-induced MVP
release in HaCaT cells. Cell culture plates were pre-incubated with WEB 2086
or vehicle 30 minutes before treatments. Cells either received no treatment,
CPAF (53.9 ng) or TPA (61.68 ng) and then incubated for 4 hours. As expected
the CPAF treated group was blocked by the pre-incubation with the PAFR
antagonist. The data depicted are mean ± SE MVP per ml per 100,000 cells.
Groups were compared using one-way ANOVA. Differences in samples were
considered significant with P value less than 0.05. P<0.001 (***).

Figure 7. Effect of inhibitors on UVB-induced MVP release in HaCaT cells. The
various inhibitors were added 1 hour before UVB treatment (3,600 J/m2) and
cells were then incubated for 4 hours. The addition of the JNK inhibitor
(SP600125), p38 MAPk inhibitor (SB203580), and ROCK1 inhibitor (Y-27632) all
blocked MVP release after UVB treatment (c-e). UVB induced MVP release was
not affected by the NK-ƙB inhibitor (PDTC), ERK ½ inhibitor (PD98,059), and a
general caspase inhibitor (Z-VAD-FMK) (a, b, f). The data depicted are mean ±
SE MVP per ml per 100,000 cells. Groups were compared using one-way
ANOVA. Differences in samples were considered significant with P value less
than 0.05. P<0.05 (*), P<0.01 (**), and P<0.001 (***).

Figure 3. MVP release from primary keratinocytes. Cell culture plates either
received no treatment, vehicle, CPAF (53.9 ng) or 3,600 J/m2 UVB and were
incubated for 4 hours. For both UVB and CPAF treatment, there was a
significant increase in MVP release compared to no treatment and vehicle
groups. The data depicted are mean ± SE MVP per ml per 100,000 cells.
Groups were compared using one-way ANOVA. Differences in samples were
considered significant with P value less than 0.05. P<0.05 (*).

Figure 1. Mechanisms of PAFR and MAPK associated MVP release under
UVB exposure. UVB induced generation of PAF and other PAFR agonists
which activates PAFR and induces MVP formation and release.

Objective
To study the potential mechanisms involved in UVB and CPAF mediated MVP
release in skin derived epithelial cell line.

Materials and Methods
Cell culture: NTERT cells were telomerase-immortalized primary human
keratinocytes and cultured in supplemented EpiLife medium. Primary
keratinocytes were obtained from surplus human skin from de-identified
donors undergoing abdominoplasty surgeries and cultured in supplemented
EpiLife medium. HaCaT cells are a spontaneously immortalized keratinocyte
cell line. The human epidermoid cell line KB cells were either with or without
transduction of the MSCV 2.1 retrovirus encoding the human leukocyte PAFR
and differentiated as KBM cells (without PAFR) and KBP cells (with PAFR). KB
and HaCaT cells were cultured in DMEM high glucose with 10% FBS.
MVP analysis: MVPs were collected from cell medium and isolated by
differential centrifugation. MVP concentration were measured using a
NanoSight NS300 instrument

Figure 4. MVP release in cells that express the PAFR (KBP) and cells that do
not express PAFR (KBM). KBP and KBM cells either received no treatment,
PMA (61.68 ng), CPAF (53.9 ng) or 3,600 J/m2 UVB and then incubated for 4
hours. In KBP cell line all treatment groups (PMA, CPAF, UVB) had significant
increase in MVP release compared to the no treatment group. However, in
KBM cells only PMA treated group had significant MVP release. There was
noted to be significant reduction in MVP release in the absence of the PAFR
for the CPAF and UVB. The data depicted are mean ± SE MVP per ml per
100,000 cells. Groups were compared using one-way ANOVA. Differences in
samples were considered significant with P value less than 0.05. P<0.05 (*),
P<0.01 (**), and P<0.001 (***).

Figure 6. Effect of inhibitors on CPAF-induced MVP release in HaCaT cells.
The various inhibitors (1.64 µg PDTC, 2.67 µg PD98,059, 0.22 µg SP600125,
3.77 µg SB203580, 0.32 µg Y-27632, or 11.22 µg Z-VAD-FMK) were added 1
hour before CPAF treatment (53.9 ng). Cells were then incubated for 4 hours.
The addition of the NF-ƙB inhibitor (PDTC), ERK ½ inhibitor (PD98,059), JNK
inhibitor (SP600125), p38 MAPK inhibitor (SB203580), and ROCK1 inhibitor
(Y-27632) all blocked MVP release after CPAF treatment (f-e). CPAF induced
MVP release was not affected by the addition of a general caspase inhibitor
(Z-VAD-FMK) (f). The data depicted are mean ± SE MVP per mL per 100,000
cells. Groups were compared using one-way ANOVA. Differences in samples
were considered significant with P value less than 0.05. P<0.001 (***).

Figure 8. CPAF- and UVB-induced MVP release are inhibited by aSMase
inhibitor (imipramine) in HaCaT cells. Cells were pre-incubated with
imipramine (6.34 µg) or vehicle 1 hour before treatments. Then, the cells either
received no treatment, CPAF (53.9 ng) or 3,600 J/m2 UVB and incubated for 4
hours. For both UVB and CPAF treated groups, imipramine significantly inhibited
the stimulus induced MVP release. The data depicted are mean ± SE MVP per
ml per 100,000 cells. Groups were compared using one-way ANOVA.
Differences in samples were considered significant with P value less than 0.05.
P<0.01 (**), and P<0.001 (***).

Summary
1. Both UVB and CPAF induce MVP release in epithelial cell lines, and UVB
mediated MVP release is PAF dependent.
2. MVP release induced by UVB and CPAF requires aSMase activity.
3. UVB and CPAF mediated MVP release share common and distinct pathways
via various MAPK signaling pathways.

